Your session is about to expire
← Back to Search
Serotonin 2C Receptor Agonist
Varenicline + Lorcaserin for Nicotine Addiction
Phase 1 & 2
Waitlist Available
Led By Ryan Hurt, MD, PhD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
No Placebo-Only Group
Summary
This will be an open label clinical trial with all subjects receiving both lorcaserin and varenicline with a primary aim of reducing post cessation weight gain.
Eligible Conditions
- Nicotine Addiction
- Body Dysmorphic Disorder
- Tobacco Use Disorder
- Obesity
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Post Cessation Weight Change
Secondary study objectives
BMI
Smoking Abstinence Rates
Waist Circumference
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Varenicline + LorcaserinExperimental Treatment2 Interventions
Open label all subjects receive both Varenicline and Lorcaserin
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Varenicline
FDA approved
Lorcaserin
FDA approved
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,321 Previous Clinical Trials
3,056,037 Total Patients Enrolled
Ryan Hurt, MD, PhDPrincipal InvestigatorMayo Clinic
4 Previous Clinical Trials
327 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger